EUVIMEDOpdag EUVIMED
Fallbericht

Successful Shrinkage of a Giant Cutaneous Squamous Cell Carcinoma with Immunotherapy in a Kidney Transplant Recipient

Theodoros Eleftheriadis, Ioannis Samaras, Antonios Spanos, Athanasios Kotsakis, Ioannis Stefanidis

Experimental and Clinical Transplantation · 2023

DOI: 10.6002/ect.2023.0018 ↗

At a glance

Fallbericht in Experimental and Clinical Transplantation, 2023. Written by Theodoros Eleftheriadis and 4 co-authors. Institution: From the Department of Nephrology, Faculty of Medicine, University of Thessaly, Larissa, Greece. Major MEDLINE topics: Carcinoma, Squamous Cell, Kidney Transplantation, Skin Neoplasms. Cited 1 times so far (Crossref); 8 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

A 56-year-old male living donor kidney transplant recipient presented with a giant cutaneous squamous cell carcinoma in his right parotid region. Programmed radiotherapy had been previously terminated due to lesion ulceration and bleeding. He was characterized as a terminal case. We applied cemiplimab, which is an immune checkpoint inhibitor against the pro-grammed cell death receptor PD-1. After 6 months, the cutaneous squamous cell carcinoma had shrunk and had stopped bleeding. The patient was treated with methylprednisolone, cyclosporine, and mycophenolate mofetil during this period. He had 2 rejection episodes defined as doubling baseline serum creatinine with no other explanation. Both episodes were successfully treated with intravenous methylprednisolone, while immunotherapy was postponed for 10 days. In both cases, serum creatinine returned to baseline within 1 week. Immune checkpoint inhibitors are indicated for invasive cutaneous squamous cell carcinoma therapy, and the risk of acute rejection should not prevent the use of these agents in kidney transplant recipients, because immune checkpoint inhibitors may enhance the quantity and quality of life of such patients.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Squamous CellKidney TransplantationSkin NeoplasmsMaleHumansMiddle AgedImmune Checkpoint InhibitorsCreatinineQuality of LifeMethylprednisoloneImmunotherapyGraft Rejection

Substances

Immune Checkpoint InhibitorsCreatinineMethylprednisolone

Authors and institutions

  • From the Department of Nephrology, Faculty of Medicine, University of Thessaly, Larissa, Greece.

Cite

APA

Eleftheriadis, T., Samaras, I., Spanos, A., Kotsakis, A., & Stefanidis, I. (2023). Successful Shrinkage of a Giant Cutaneous Squamous Cell Carcinoma with Immunotherapy in a Kidney Transplant Recipient. Experimental and Clinical Transplantation. https://doi.org/10.6002/ect.2023.0018

Vancouver

Eleftheriadis T, Samaras I, Spanos A, Kotsakis A, Stefanidis I. Successful Shrinkage of a Giant Cutaneous Squamous Cell Carcinoma with Immunotherapy in a Kidney Transplant Recipient. Experimental and Clinical Transplantation. 2023. doi:10.6002/ect.2023.0018

BibTeX
@article{Eleftheriadis2023,
  author = {Eleftheriadis, Theodoros and Samaras, Ioannis and Spanos, Antonios and Kotsakis, Athanasios and Stefanidis, Ioannis},
  title = {Successful Shrinkage of a Giant Cutaneous Squamous Cell Carcinoma with Immunotherapy in a Kidney Transplant Recipient},
  journal = {Experimental and Clinical Transplantation},
  year = {2023},
  doi = {10.6002/ect.2023.0018}
}
Start for free →